IVERIC bio (IVERIC bio) Cash Flow from Financing : $429.41 Mil (TTM As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

What is IVERIC bio Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2023, IVERIC bio paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, IVERIC bio spent $0.00 Mil on financial activities for the three months ended in Mar. 2023.

IVERIC bio Cash Flow from Financing Historical Data

The historical data trend for IVERIC bio's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVERIC bio Cash Flow from Financing Chart

IVERIC bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash Flow from Financing

Get a 7-Day Free Trial

6.14

42.84

150.58

272.34

428.91

IVERIC bio Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash Flow from Financing	Get a 7-Day Free Trial															2.08	2.80	49.72	374.31	2.59

IVERIC bio Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

IVERIC bio's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

	Cash Flow from Financing		(A: Dec. 2022 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	324.29	+	0	+	100	+	0	+	0	+	4.615
=	428.91

IVERIC bio's Cash from Financing for the quarter that ended in Mar. 2023 is:

	Cash Flow from Financing		(Q: Mar. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $429.41 Mil.

IVERIC bio (NAS:ISEE) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

IVERIC bio's issuance of stock for the three months ended in Mar. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

IVERIC bio's repurchase of stock for the three months ended in Mar. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

IVERIC bio's net issuance of debt for the three months ended in Mar. 2023 was $0.00 Mil. IVERIC bio received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

IVERIC bio's net issuance of preferred for the three months ended in Mar. 2023 was $0.00 Mil. IVERIC bio paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

IVERIC bio's cash flow for dividends for the three months ended in Mar. 2023 was $0.00 Mil. IVERIC bio received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

IVERIC bio's other financing for the three months ended in Mar. 2023 was $0.00 Mil. IVERIC bio received $0.00 Mil on other financial activities.

IVERIC bio Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of IVERIC bio's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

IVERIC bio (IVERIC bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IVERIC bio Inc (NAS:ISEE) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Sylvan Way, Parsippany, New Jersey, USA, 07054

Website

https://www.ivericbio.com

IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.

Executives

Keith Westby	officer: SVP & COO	ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
David Francis Carroll	officer: SVP, CFO and Treasurer	ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Glenn Sblendorio	director	3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Christopher Paul Simms	officer: Senior Vice President, CCO	FIVE PENN PLAZA SUITE 2372, NEW YORK NY 10001
Anthony S Gibney	officer: EVP, Chief Business Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Calvin W. Roberts	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Christine Ann Miller	director	5 PENN PLAZA, SUITE 2372, NEW YORK NY 10001
Pravin Dugel	officer: EVP, Chief Strategy & Business	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
David R Guyer	director, officer: Chief Executive Officer	ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
Mark S. Blumenkranz	director	C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Adrienne L Graves	director	125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Versant Venture Capital Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Jane Henderson	director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142